[1] Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44(38):3720-3826. DOI: 10.1093/eurheartj/ehad191.[2] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2018, 39(2):119-177. DOI: 10.1093/eurheartj/ehx393.[3] Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2021, 42(14):1289-1367. DOI: 10.1093/eurheartj/ehaa575.[4] Gray AJ, Roobottom C, Smith JE, et al. Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial[J]. BMJ, 2021, 374:n2106. DOI: 10.1136/bmj.n2106.[5] Kite TA, Kurmani SA, Bountziouka V, et al. Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials[J]. Eur Heart J, 2022, 43(33):3148-3161. DOI: 10.1093/eurheartj/ehac213.[6] Li Y, Liang Z, Qin L, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial[J]. Lancet, 2022, 400(10366):1847-1857. DOI: 10.1016/S0140-6736(22)01999-7.[7] Montalescot G, van 't Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction[J]. N Engl J Med, 2014, 371(11):1016-1027. DOI: 10.1056/NEJMoa1407024.[8] Koul S, Smith JG, Götberg M, et al. No benefit of ticagrelor pretreatment compared with treatment during percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Circ Cardiovasc Interv, 2018, 11(3):e005528. DOI: 10.1161/CIRCINTERVENTIONS.117.005528.[9] Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial[J]. Lancet, 2020, 395(10233):1374-1381. DOI: 10.1016/S0140-6736(20)30325-1.[10] Szummer K, Montez-Rath ME, Alfredsson J, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART registry[J]. Circulation, 2020, 142(18):1700-1708. DOI: 10.1161/CIRCULATIONAHA.120.050645.[11] Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk[J]. N Engl J Med, 2021, 385(18):1643-1655. DOI: 10.1056/NEJMoa2108749.[12] Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial[J]. Lancet, 2021, 397(10293):2487-2496. DOI: 10.1016/S0140-6736(21)01063-1.[13] Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis[J]. Lancet, 2020,395(10235):1487-1495. DOI: 10.1016/S0140-6736(20)30315-9.[14] Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction[J]. N Engl J Med, 2019, 381(15):1411-1421. DOI: 10.1056/NEJMoa1907775.[15] Gallone G, Angelini F, Fortuni F, et al. Angiography- vs. physiology-guided complete revascularization in patients with ST-elevation myocardial infarction and multivessel disease: who is the better gatekeeper in this setting? A meta-analysis of randomized controlled trials[J]. Eur Heart J Qual Care Clin Outcomes, 2020, 6(3):199-200. DOI: 10.1093/ehjqcco/qcaa007.[16] Lemkes JS, Janssens GN, van der Hoeven NW, et al. Coronary angiography after cardiac arrest without ST-Segment elevation[J]. N Engl J Med, 2019, 380(15):1397-1407. DOI: 10.1056/NEJMoa1816897.[17] Desch S, Freund A, Akin I, et al. Angiography after out-of-hospital cardiac arrest without ST-segment elevation[J]. N Engl J Med, 2021, 385(27):2544-2553. DOI: 10.1056/NEJMoa2101909.[18] Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest[J]. N Engl J Med, 2021, 384(24):2283-2294. DOI: 10.1056/NEJMoa2100591.[19] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51(03):221-255. DOI:10.3760/cma.j.cn112148-20230119-00038.[20] Nidorf SM, Fiolet A, Mosterd A, et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med, 2020, 383(19):1838-1847. DOI: 10.1056/NEJMoa2021372.[21] Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med, 2019, 381(26):2497-2505. DOI: 10.1056/NEJMoa1912388.编辑:白洋审核:白洋